These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36372934)

  • 1. Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration.
    Mukai Y; Yoshida T; Kondo T; Miura J; Inotsume N; Toda T
    Ther Drug Monit; 2022 Dec; 44(6):762-770. PubMed ID: 36372934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
    Mukai Y; Yoshida Y; Yoshida T; Kondo T; Inotsume N; Toda T
    Ther Drug Monit; 2021 Jun; 43(3):386-393. PubMed ID: 33065614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
    Kralj E; Trontelj J; Pajič T; Kristl A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
    Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
    Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
    Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients.
    Iacuzzi V; Posocco B; Zanchetta M; Montico M; Marangon E; Poetto AS; Buzzo M; Gagno S; Buonadonna A; Guardascione M; Casetta B; Toffoli G
    PLoS One; 2019; 14(11):e0225225. PubMed ID: 31743371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.
    Boons CCLM; Chahbouni A; Schimmel AM; Wilhelm AJ; den Hartog YM; Janssen JJWM; Hendrikse NH; Hugtenburg JG; Swart EL
    J Pharm Pharmacol; 2017 Oct; 69(10):1265-1274. PubMed ID: 28643375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
    Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
    Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia.
    Lee J; Jung SY; Choi MY; Park JS; Park SK; Lim SA; Cho KH; Oh SY; Ha J; Kim DW; Lee J
    J Clin Pharm Ther; 2020 Oct; 45(5):1006-1013. PubMed ID: 32022312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
    Sumimoto T; Nakahara R; Suzuki Y; Tanaka R; Yoshida N; Ogata M; Itoh H
    Ther Drug Monit; 2022 Jun; 44(3):419-429. PubMed ID: 34469417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS/MS method.
    Verougstraete N; Stove V; Verstraete AG; Stove C
    Talanta; 2021 May; 226():122140. PubMed ID: 33676691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
    Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
    J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors.
    Verougstraete N; Stove CP
    J Pharm Biomed Anal; 2022 Jan; 207():114418. PubMed ID: 34655987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children.
    Dilo A; Daali Y; Desmeules J; Chalandon Y; Uppugunduri CRS; Ansari M
    Ther Drug Monit; 2020 Feb; 42(1):111-117. PubMed ID: 31348116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.
    Martial LC; van den Hombergh E; Tump C; Halmingh O; Burger DM; van Maarseveen EM; Brüggemann RJ; Aarnoutse RE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1089():16-23. PubMed ID: 29747155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
    Weatherald J; Bondeelle L; Chaumais MC; Guignabert C; Savale L; Jaïs X; Sitbon O; Rousselot P; Humbert M; Bergeron A; Montani D
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32527740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
    Haguet H; Bouvy C; Delvigne AS; Modaffari E; Wannez A; Sonveaux P; Dogné JM; Douxfils J
    Front Pharmacol; 2020; 11():1007. PubMed ID: 32719607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
    Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
    Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.